- Home
- RIGL vs LRMR Comparison
RIGL vs LRMR Comparison
Compare RIGL & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- LRMR
- Stock Information
- Founded
- RIGL 1996
- LRMR N/A
- Country
- RIGL United States
- LRMR United States
- Employees
- RIGL N/A
- LRMR N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- RIGL Health Care
- LRMR Health Care
- Exchange
- RIGL Nasdaq
- LRMR Nasdaq
- Market Cap
- RIGL 335.5M
- LRMR 309.8M
- IPO Year
- RIGL 2000
- LRMR N/A
- Fundamental
- Price
- RIGL $30.17
- LRMR $4.66
- Analyst Decision
- RIGL Buy
- LRMR Strong Buy
- Analyst Count
- RIGL 5
- LRMR 7
- Target Price
- RIGL $38.20
- LRMR $16.71
- AVG Volume (30 Days)
- RIGL 668.8K
- LRMR 4.4M
- Earning Date
- RIGL 11-06-2025
- LRMR 10-29-2025
- Dividend Yield
- RIGL N/A
- LRMR N/A
- EPS Growth
- RIGL N/A
- LRMR N/A
- EPS
- RIGL 5.43
- LRMR N/A
- Revenue
- RIGL $267,921,000.00
- LRMR N/A
- Revenue This Year
- RIGL $59.93
- LRMR N/A
- Revenue Next Year
- RIGL N/A
- LRMR N/A
- P/E Ratio
- RIGL $5.32
- LRMR N/A
- Revenue Growth
- RIGL 105.62
- LRMR N/A
- 52 Week Low
- RIGL $13.57
- LRMR $1.61
- 52 Week High
- RIGL $43.72
- LRMR $9.50
- Technical
- Relative Strength Index (RSI)
- RIGL 39.94
- LRMR 55.70
- Support Level
- RIGL $27.75
- LRMR $3.10
- Resistance Level
- RIGL $29.46
- LRMR $4.99
- Average True Range (ATR)
- RIGL 1.49
- LRMR 0.52
- MACD
- RIGL -0.41
- LRMR 0.02
- Stochastic Oscillator
- RIGL 25.90
- LRMR 68.50
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.